Prothena Corp Public (PRTA) Net Cash Flow (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Net Cash Flow came in at $21.9 million in Q1 2026, up 141.03% year-on-year from $9.1 million in Q1 2025, and up 194.08% quarter-over-quarter from -$23.3 million in Q4 2025.
Prothena Corp Public (PRTA) Net Cash Flow (2012 - 2026) Analysis & Trends
Prothena Corp Public's Net Cash Flow history runs 15 years deep, the most recent figure standing at $21.9 million for Q1 2026.
- On a quarterly basis, Net Cash Flow rose 141.03% year-over-year to $21.9 million in Q1 2026; TTM through Mar 2026 was -$88.5 million, a 31.91% increase from a year earlier, with the FY2025 full-year figure at -$163.9 million, down 10.12% from the prior year.
- Net Cash Flow grew to $21.9 million in Q1 2026 per PRTA's latest filing, from -$23.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $215.6 million in Q4 2022 and bottomed at -$72.3 million in Q1 2024.
- The 5-year median for Net Cash Flow is -$34.2 million (2022), against an average of -$14.7 million.
- Across the five-year window, Net Cash Flow jumped 1126.65% in 2022 and sank 480.64% in 2024, its largest moves.
- Year by year, Net Cash Flow stood at $215.6 million in 2022, then plunged by 124.15% to -$52.1 million in 2023, then grew by 8.05% to -$47.9 million in 2024, then surged by 51.31% to -$23.3 million in 2025, then soared by 194.08% to $21.9 million in 2026.
- Per Business Quant, the three latest PRTA Net Cash Flow figures stand at $21.9 million (Q1 2026), -$23.3 million (Q4 2025), and -$40.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | 21.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.93 Mn |
| Mar 31, 2026 | 21.93 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Sep 30, 2025 | -40.59 Mn |
| Sep 30, 2025 | -40.59 Mn |
| Jun 30, 2025 | -46.50 Mn |
| Jun 30, 2025 | -46.50 Mn |
| Mar 31, 2025 | -53.45 Mn |
| Mar 31, 2025 | -53.45 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Sep 30, 2024 | -44.86 Mn |
| Sep 30, 2024 | -44.86 Mn |
| Jun 30, 2024 | 16.26 Mn |
| Jun 30, 2024 | 16.26 Mn |
| Mar 31, 2024 | -72.32 Mn |
| Mar 31, 2024 | -72.32 Mn |
| Dec 31, 2023 | -52.07 Mn |
| Dec 31, 2023 | -52.07 Mn |